Skip to main content

Advertisement

Table 3 Univariate associations between change in DXR-BMD, baseline characteristics and baseline serological biomarkers (univariate linear regression analyses)

From: Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

  One-year change in DXR-BMD (%) Two-year change in DXR-BMD (%) Five-year change in DXR-BMD (%)
  B
(95% CI)
P value B
(95% CI)
P value B
(95% CI)
P value
Age (years) -0.1
(-0.1 to 0.0)
0.03 -0.1
(-0.2 to 0.0)
0.002 -0.2
(-0.3 to 0.0)
0.004
Sex (female) -0.1
(-1.4 to 1.2)
0.90 0.6
(-1.3 to 2.4
0.54 0.0
(-3.0 to 3.1)
0.98
Disease duration (years) 0.1
(-0.4 to 0.6)
0.74 0.2
(-0.5 to 0.9)
0.66 0.8
(-0.4 to 1.9)
0.18
HAQ -1.4
(-2.2 to -0.5)
0.003 -1.9
(-3.1 to -0.7)
0.003 -2.3
(-4.5 to -0.2)
0.03
ESR (> 20 mm/h) -2.9
(-4.0 to -1.9)
< 0.001 -4.2
(-5.7 to -2.8)
< 0.001 -6.6
(-9.0 to -4.1)
> 0.001
CRP (> 10 mg/l) -1.6
(-2.8 to -0.3)
0.01 -3.4
(-5.1 to -1.7)
< 0.001 -3.9
(-6.8 to -1.0)
0.008
Anti-CCP (> 25 U/ml) -2.3
(-3.4 to -1.2)
< 0.001 -3.5
(-5.1 to -2.0)
< 0.001 -6.5
(-9.0 to -4.0)
< 0.001
IgA RF (> 25 U/ml) -0.7
(-1.9 to 0.5)
0.26 -2.6
(-4.3 to -1.0)
0.002 -5.0
(-7.6 to -2.3)
< 0.001
IgM RF(> 25 U/ml) -1.2
(-2.3 to -0.1)
0.04 -2.8
(-4.4 to -1.3)
< 0.001 -5.5
(-8.0 to -3.0)
< 0.001
DMARD treatment -1.6
(-2.6 to -0.5)
0.003 -2.6
(-4.3 to -0.9)
0.004 -5.0
(-7.9 to -2.2)
0.001
Prednisolone use -1.0
(-2.2 to 0.1)
0.07 -1.9
(-3.5 to -0.4)
0.02 -3.6
(-6.2 to -1.0)
0.008
  1. Results from univariate linear regression analyses with DXR-BMD as dependent variable.
  2. Anti-CCP = antibodies to cyclic citrullinated peptide; CI = confidence interval; CRP = C-reactive protein; DMARD = disease-modifying antirheumatic drugs; DXR-BMD = hand bone mineral density estimated by digital X-ray radiogrammetry; ESR = erythrocyte sedimentation rate; HAQ = health assessment questionnaire; Ig = immunoglobulin; RA = rheumatoid arthritis; RF = rheumatoid arthritis.